New hope for Hard-to-Treat myeloma: early trial tests CC-95266

NCT ID NCT04674813

Completed Disease control Sponsor: Juno Therapeutics, a Subsidiary of Celgene Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated Apr 26, 2026 · Updated 15 times

Summary

This early-stage study tested a new treatment called CC-95266 in 130 adults with multiple myeloma that had come back or stopped responding to other therapies. The main goals were to check safety and find the best dose. Researchers also looked at how well the treatment worked, such as tumor shrinkage. Because this is a cell therapy that may need ongoing management, it is not a cure but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 001

Nashville, Tennessee, 37203, United States
Local Institution - 002

Denver, Colorado, 80218, United States
Local Institution - 003

Seattle, Washington, 98104, United States
Local Institution - 005

Birmingham, Alabama, 10016, United States
Local Institution - 006

Dallas, Texas, 75390, United States
Local Institution - 008

Baltimore, Maryland, 21201, United States
Local Institution - 009

Duarte, California, 91010-301, United States
Local Institution - 010

Boston, Massachusetts, 02215, United States
Local Institution - 011

New York, New York, 10029, United States
Local Institution - 012

San Francisco, California, 94143, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA